New User:

Forgot your password?

Stock Market & Financial Investment News

News For PRGO From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
February 12, 2016
08:46 EDTPRGOAkorn remains a potential takeout target, says RBC Capital
RBC Capital analyst Randall Stanicky says he remains optimistic that Akorn (AKRX) can complete the audit process by May 9 and that the company remains a potential takeout candidate despite one less near-term buyer in Mylan (MYL). Mylan's purchase of Meda puts a potential buyer on the sidelines for now, Stanicky tells investors in a research note. He had viewed Mylan as the most likely suitor followed by Perrigo (PRGO). Applying the price paid for Meda yields a $47 per share buyout price target for Akorn, the analyst notes. He lowered his price target for Akorn shares to $37 from $52 and keeps an Outperform rating on the name.
February 3, 2016
06:13 EDTPRGOPfizer insists Allergan deal won't be thwarted by U.S. politicians, FT says
Pfizer (PFE) has insisted that its $160B acquisition of Allergan (AGN) will not be stifled by political opposition, amid criticism that the deal will cost the U.S. Treasury billions of dollars in future tax revenues, the Financial Times reports. Pfizer CEO Ian Read also reiterated his intention to postpone until 2018 a decision on whether to break of the combined entity into two or three smaller companies, but has said that he would be open to offers for its generics unit, the report says. Mylan (MYL) has been connected to a potential acquisition of Pfizer's generic drugs business after it failed in its attempt to buy Perrigo (PRGO) last year, the report says. Reference Link

Sign up for a free trial to see the rest of the stories you've been missing.
I agree to the disclaimer & terms of use